Herantis Pharma Oyj
HRPMF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $68,338 | $54,603 | $48,036 | $31,500 |
| - Cash | $635 | $5,503 | $5,036 | $5,630 |
| + Debt | $30 | $35 | $4,541 | $4,691 |
| Enterprise Value | $67,733 | $49,134 | $47,541 | $30,561 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$4,934 | $831 | $7,979 | $6,921 |
| % Margin | – | – | – | – |
| Net Income | -$4,939 | $280 | -$9,324 | -$23,576 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.24 | 0.016 | -0.64 | -2.2 |
| % Growth | -1,572.4% | 102.5% | 70.9% | – |
| Operating Cash Flow | -$6,545 | -$4,636 | -$8,944 | -$9,934 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$6,545 | -$4,636 | -$8,944 | -$9,934 |